Unifi nootropics from the lab to the web: a story of academic (and industrial) shortcomings

References

• Jarvik ME, Kopp R. An improved one trial passive avoidance learning situation. Psychol Rep 1967;21:221–4
   PubMed Web of Science ®Google Scholar
• Mondadori C, Preiswerg G, Jaekel J. Treatment with a GABAB receptor blocker improves the cognitive performance of mice rats and rhesus monkeys. Pharmacol Commun 1992;2:93–7
   Google Scholar
• Morris RGM. Development of a water–maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984;11:47–60
   PubMed Web of Science ®Google Scholar
• Manetti D, Borea PA, Ghelardini C, et al. Reduced flexibility hybrids of the nicotinic agonist 1,1-dimethyl-4-acetylpiperazinium iodide and 2-(dimethylamino)methyl-5-methyl cyclopentanone methyiodide. Med Chem Res 1997;7:301–12
   Web of Science ®Google Scholar
• Manetti D, Ghelardini C, Bartolini A, et al. Design, synthesis and preliminary pharmacological evaluation of 1,4-diazabicyclo[4.3.0.]nonan-9-ones as a new class of highly potent nootropic drugs. J Med Chem 2000;43:1969–74
   PubMed Web of Science ®Google Scholar
• Manetti D, Ghelardini C, Bartolini A, et al. Molecular simplification of 1,4-diazabicyclo[4.3.0]nonan-9-ones gives piperazine derivatives that maintain high nootropic activity. J Med Chem 2000;43:4499–507
   PubMed Web of Science ®Google Scholar
• Martini E, Ghelardini C, Bertucci C, et al. Enantioselective synthesis and preliminary pharmacological evaluation of the enantiomers of unifiram (DM232), a potent cognition-enhancing agent. Med Chem 2005;1:473–80
   PubMed Web of Science ®Google Scholar
• Scapecchi S, Martini E, Manetti D, et al. Structure–activity relationship studies on unifiram (DM232) and sunifiram (DM235), two novel and potent cognition enhancing drugs. Bioorg Med Chem 2004;12:71–85
   PubMed Web of Science ®Google Scholar
• Zarrinmayen H, Bleakman D, Gates MR, et al. [3H]N-2-(4-(N-benzamido)phenyl)propyl-2-propanesulfonamide. A novel AMPA receptor potentiator and radioligand. J Med Chem 2001;44:302–4
   PubMed Web of Science ®Google Scholar
• Martini E, Di Cesare Mannelli L, Bartolucci L, et al. Synthesis and biological evaluation of 3,7-diazabicyclo[4.3.0]nonan-8-one as potential nootropic and analgesic drugs. J Med Chem 2011;54:2512–16
   PubMed Web of Science ®Google Scholar
• Yamada KA. Therapeutic potential of positive AMPA receptors modulators in the treatment of neurological disease. Exp Opin Inv Drug 2000;9:765–78
   PubMed Web of Science ®Google Scholar
• Martini E, Ghelardini C, Dei S, et al. Design, synthesis and preliminary pharmacological evaluation of new piperidine and piperazine derivatives as cognition enhancers. Bioorg Med Chem 2008;16:1431–43
   PubMed Web of Science ®Google Scholar
• Manetti D, Martini E, Ghelardini C, et al. 4-Aminopiperidine derivatives as a new class of potent cognition enhancing drugs. Bioorg Med Chem Lett 2003;13:2303–6
   PubMed Web of Science ®Google Scholar
• Martini E, Norcini M, Ghelardini C, et al. Design synthesis and preliminare pharmacological evaluation of new analogues of DM232 (unifiram) and DM235 (sunifiram) as cognition modulator. Bioorg Med Chem 2008;16:10034–47
   PubMed Web of Science ®Google Scholar
• Martini E, Salvicchi A, Ghelardini C, et al. Design, synthesis and nootropic activity of new analogues of sunifiram and sapunifiram, two potent cognition enhancers. Bioorg Med Chem 2009;17:7606–814
   PubMed Web of Science ®Google Scholar
• Ghelardini C, Galeotti N, Gualtieri F, et al. The novel nootropic compound DM232 (UNIFIRAM) ameliorates memory impairment in mice and rats. Drug Dev Res 2002;56:23–32
   Web of Science ®Google Scholar
• Ghelardini C, Galeotti N, Gualtieri F, et al. DM235 (Sunifiram): a novel nootropic with potential as cognitive enhancer. Naunyn-Schmiedeberg’s Arch Pharmacol 2002;365:419–26
   Google Scholar
• Galeotti N, Ghelardini C, Bartolini A, et al. AMPA-receptor activation is involved in the antiamnesic effect of DM232 (unifiram) and DM235 (sunifiram). Naunyn-Schmiedeberg’s Arch Pharmacol 2003;368:538–45
   Google Scholar
• Raimondi L, Ghelardini C, Gualtieri F, et al. DM232 and DM235, two potent cognition-enhancers, increase NO levels in rat adipocytes. Proceedings of Frontiers in CNS and Oncology Medicinal Chemistry, Siena, Italy; 2007 Oct 7–9, p 47
   Google Scholar
• Goulaiev AH, Senning A. Piracetam and other structurally related nootropics. Brain Res Rev 1994;19:180–222
   PubMedGoogle Scholar
• Gualtieri F, Manetti D, Romanelli MN, Ghelardini C. Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs. Curr Pharm Des 2002;8:125–38
   PubMed Web of Science ®Google Scholar
• Gualtieri F, Guandalini L, Manetti D, et al. Cognition-enhancing drugs in mild cognitive impairment (MCI) and Alzheimer’s disease (AD): an update[1]. Med Chem Rev-Online 2005;2:471–87
   Google Scholar
• Romanelli MN, Galeotti N, Ghelardini C, et al. Pharmacological characterization of DM232 (unifiram) and DM235 (sunifiram) new potent cognition enhancers. CNS Drug Rev 2006;12:39–53
   PubMedGoogle Scholar
• Froestl W, Muhs A, Pfeiffer A. Cognitive enhancers (nootropics). Part 1 Drugs interacting with receptors. Update 2014. J Alzheimer’s Dis 2014;41:961–1019
   PubMed Web of Science ®Google Scholar
• Froestl W, Muhs A, Pfeiffer A. Cognitive enhancers (nootropics). Part 2 Drugs interacting with enzymes. Update.2014. J Alzheimer’s Dis 2014;42:1–68
   PubMed Web of Science ®Google Scholar
• Froestl W, Muhs A, Pfeiffer A. Cognitive enhancers (nootropics). Part 3 Drugs interacting with targets other than receptors and enzymes. Disease modifying drugs. J Alzheimer’s Dis 2014;42:1079–149
   PubMed Web of Science ®Google Scholar
• Naftalin RJ, Cunningham P, Afzal-Ahmed I. Piracetam and TRH analogues antagonize inhibition by barbiturates, diazepam, melatonin and galanin of human erythrocyte D-glucose transport. Br J Pharmacol 2004;142:594–608
   PubMed Web of Science ®Google Scholar
• Moriguchi S, Tanaka T, Tagashira H, et al. Novel nootropic drug sunifiram improves cognitive deficits via CaM kinase II and protein kinase C activation in olfactory bulbectomized mice. Behav Brain Res 2013;242:150–7
   PubMed Web of Science ®Google Scholar
• Moriguchi S, Tanaka T, Narahashi T, Fukunaga K. Novel nootropic drug sunifiram enhances hippocampal synaptic efficacy via glycine-binding site of N-methyl-d-aspartate receptor. Hippocampus 2013;23:942–51
   PubMed Web of Science ®Google Scholar
• Bartolini A, Bellucci C, Galeotti N, et al. (University of Florence). Derivatives possessing nootropic activity, preparation and use. EP1118612 (A1), July 25, 2001. Application number: EP20000101165 20000121
   Google Scholar
• Lanni C, Lenzken SC, Pascale A, et al. Cognition enhancers between treating and doping the mind. Pharmacol Res 2008;57:196–213
   PubMed Web of Science ®Google Scholar
• Bostrom N, Sandberg A. Cognitive enhancement: methods, ethics, regulatory challenges. Sci Eng Ethics 2009;15:311–41
   PubMed Web of Science ®Google Scholar
• Kluger J. Safety concerns raised over popular wakefulness drug. Time 2009, March 17. Available from: http://content.time.com/time/health/article/0,8599,1885825,00.html [last accessed 27 Feb 2015]
   Google Scholar